MeiraGTx Holdings PLC
MGTX
View Detailed Chart
7.430USD
+0.230+3.19%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
597.96MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+3.19%
5 Days
-2.37%
1 Month
-1.07%
6 Months
-6.54%
Year to Date
-6.54%
1 Year
+6.91%
View Detailed Chart
TradingKey Stock Score of MeiraGTx Holdings PLC
Currency: USD Updated: 2026-02-06Key Insights
MeiraGTx Holdings PLC's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 137 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 27.38.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MeiraGTx Holdings PLC's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
MeiraGTx Holdings PLC Highlights
StrengthsRisks
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 109.04% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 33.28M.
Fairly Valued
The company’s latest PE is -3.53, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.32M shares, decreasing 8.25% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 4.26K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.18.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
27.375
Target Price
+280.21%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
MeiraGTx Holdings PLC News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
MeiraGTx Holdings PLC Info
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company. It has a pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It is focused on vivo delivery of vectorized biologic therapeutics addressing unmet needs in prevalent disorders, including severe forms of xerostomia, neurodegenerative diseases and ocular diseases, including inherited retinal diseases (IRDs), and large degenerative ocular diseases. The Company’s product pipeline includes Botaretigene Sparoparvovec for the treatment of X-linked Retinitis Pigmentosa; AAV-hAQP1 for the treatment of Radiation-Induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-Associated Retinal Dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of Achromatopsia; AAV-AIPL1 for the treatment of LCA4, and others.
Ticker SymbolMGTX
CompanyMeiraGTx Holdings PLC
CEOForbes (Alexandria)
Websitehttps://meiragtx.com/
Related Instruments
+3.66%
+3.17%
+0.93%
+1.99%
+1.78%
+1.60%
-0.95%
+4.49%
+2.10%
+10.00%
+2.72%
+4.15%
+1.81%
+4.17%
+0.72%
+1.06%
+2.46%
0.00%
+0.53%
+0.56%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
67893.950
-2076.180 (-2.97%)
282.580
+22.390 (+8.61%)
2005.040
-46.690 (-2.28%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
